Bluebird Bio

Here's Why bluebird bio Dropped 13.3% in September
Here's Why bluebird bio Dropped 13.3% in September
Motley Fool
Bluebird Bio
Amgen
Flag link:
EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder
EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder
CP Wire
Bluebird Bio
transfusion-dependent anemia
LentiGlobin
EMA
Europe
Flag link:
EMA Accepts Bluebird Bio's Marketing Authorization Application for Gene Therapy for Rare Blood Disorder
Bluebird Bio
transfusion-dependent anemia
LentiGlobin
Flag link:
Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
Motley Fool
Bluebird Bio
Amgen
Celgene
AMG-420
bb2121
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Adamis
GSK
Sangamo BioSciences
Roche
Bluebird Bio
ProQR Therapeutics
Geron
Amarin
Palatin
EyeGate
Galactin
Omeros
Atossa Genetics
Flag link:
Bluebird taps Gritstone for oncology cell therapy targets
Bluebird taps Gritstone for oncology cell therapy targets
Fierce Biotech
Bluebird Bio
Gritstone Oncology
oncology
T-cell receptors
drug development
Flag link:
Express Scripts staking out million-dollar gene therapies
Express Scripts staking out million-dollar gene therapies
Reuters
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
Flag link:
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Forbes
Regeneron
Bluebird Bio
CAR-T
drug discovery
gene therapy
cancer
Flag link:
Bluebird’s first gene therapy gets European fast track
Bluebird’s first gene therapy gets European fast track
PM Live
Bluebird Bio
gene therapy
EMA
LentiGlobin
Flag link:
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Celgene tweaks trial of myeloma CAR-T bb2121, raising dose
Fierce Biotech
Celgene
clinical trials
bb2121
Bluebird Bio
Multiple Myeloma
CAR-T
Flag link:
Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far
Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far
Motley Fool
Bluebird Bio
gene therapy
beta thalassemia
LentiGlobin
Flag link:
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Yahoo/Benzinga
Bluebird Bio
Celgene
LentiGlobin
Madrigal Pharmaceuticals
Flag link:
Demand For Gene Therapies To Prompt Surge In Pharma M&A
Demand For Gene Therapies To Prompt Surge In Pharma M&A
Forbes
gene therapy
M&A
Bluebird Bio
Sangamo Therapeutics
Flag link:
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
CP Wire
Bluebird Bio
sickle cell disease
LentiGlobin
gene therapy
Flag link:
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
CP Wire
Bluebird Bio
gene therapy
LentiGlobin
beta thalassemia
sickle cell disease
Flag link:
Bluebird Bio Announces More Good News for LentiGlobin Gene Therapy – Exciting Results in Sickle Cell Disease
Bluebird Bio
sickle cell disease
LentiGlobin
Flag link:
Bluebird Bio Presents Promising Results for Gene Therapy in Rare Blood Disorder
Bluebird Bio
β-thalassemia
sickle cell disease
LentiGlobin
Flag link:
ASCO18: Who were the big winners and losers?
ASCO18: Who were the big winners and losers?
Biopharma Dive
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
Flag link:
#ASCO18: A Weekend of Surprises
#ASCO18: A Weekend of Surprises
Motley Fool
ASCO 2018
Bluebird Bio
Loxo Oncology
Nektar Therapeutics
Celgene
Grail
Flag link:
Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
Bluebird Bio's "Impressive" Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
Forbes
Bluebird Bio
CAR-T
Multiple Myeloma
bb2121
ASCO 2018
Flag link:

Pages